BioCryst Pharmaceuticals, Inc. (BCRX)
9.90
-0.02
(-0.20%)
USD |
NASDAQ |
Sep 02, 10:42
BioCryst Pharmaceuticals Cash from Operations (TTM) : 358.99M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 358.99M |
| March 31, 2026 | 295.78M |
| December 31, 2025 | 329.88M |
| September 30, 2025 | 49.98M |
| June 30, 2025 | 16.56M |
| March 31, 2025 | -25.98M |
| December 31, 2024 | -52.02M |
| September 30, 2024 | -57.07M |
| June 30, 2024 | -84.66M |
| March 31, 2024 | -101.70M |
| December 31, 2023 | -95.14M |
| September 30, 2023 | -110.07M |
| June 30, 2023 | -122.62M |
| March 31, 2023 | -131.56M |
| December 31, 2022 | -161.85M |
| September 30, 2022 | -170.46M |
| June 30, 2022 | -161.29M |
| March 31, 2022 | -158.95M |
| December 31, 2021 | -142.16M |
| September 30, 2021 | -154.34M |
| June 30, 2021 | -169.32M |
| March 31, 2021 | -174.95M |
| December 31, 2020 | -137.22M |
| September 30, 2020 | -103.02M |
| June 30, 2020 | -92.41M |
| Date | Value |
|---|---|
| March 31, 2020 | -85.87M |
| December 31, 2019 | -89.58M |
| September 30, 2019 | -103.12M |
| June 30, 2019 | -110.52M |
| March 31, 2019 | -99.91M |
| December 31, 2018 | -92.56M |
| September 30, 2018 | -79.10M |
| June 30, 2018 | -56.50M |
| March 31, 2018 | -52.27M |
| December 31, 2017 | -41.14M |
| September 30, 2017 | -36.48M |
| June 30, 2017 | -41.61M |
| March 31, 2017 | -43.12M |
| December 31, 2016 | -53.44M |
| September 30, 2016 | -62.41M |
| June 30, 2016 | -57.51M |
| March 31, 2016 | -28.23M |
| December 31, 2015 | -13.12M |
| September 30, 2015 | -12.18M |
| June 30, 2015 | -8.118M |
| March 31, 2015 | -33.32M |
| December 31, 2014 | -38.55M |
| September 30, 2014 | -29.18M |
| June 30, 2014 | -28.50M |
| March 31, 2014 | -24.29M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Amgen, Inc. | 12.48B |
| Vertex Pharmaceuticals, Inc. | 4.293B |
| Agenus, Inc. | -98.50M |
| Anika Therapeutics, Inc. | 5.977M |
| Imunon, Inc. | -15.11M |